Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis

Clinical and Experimental Immunology

Volumn 118, Issue 2, 1999, Pages 315-321

  Oliver, Stephen J ^a   Freeman, S L ^a   Corral, L G ^a   Ocampo, C J ^a   Kaplan, G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Adjuvant arthritis; IL 2; Rat; Thalidomide analogues; Tumour necrosis factor alpha

Indexed keywords

CC 1069; CONCANAVALIN A; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ARTICLE; CELL STIMULATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; FEMALE; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SPLEEN CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; EDEMA; EXTREMITIES; FEMALE; INTERLEUKIN-2; LEUKOCYTES; LYMPHOCYTE ACTIVATION; RATS; RATS, INBRED LEW; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032757642     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01039.x     Document Type: Article

References (31)

1. 1 Harris ED Jr. Rheumatoid arthritis pathophysiology and implications for treatment. N Eng J Med 1990; 322:1277-89.
2. 2 Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin N Am 1998; 24:593-614.
3. 3 Elliot MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
4. 4 Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125-27.
5. 5 Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337:141-7.
6. 6 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
7. 7 Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-14.
8. 8 Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitor activity. Molec Med 1996; 2:506-15.
9. 9 Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956; 91:95-101.
10. 10 Glenn EM, Gray J. Adjuvant-induced polyarthritis in rats: biologic and histologic background. Am J Vet Res 1964; 26:1180-94.
11. 11 Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5:298-304.
12. 12 Issekutz AC, Meager A, Ottemess I, Issekutz TB. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994; 97:26-32.
13. 13 Sekut L, Yarnall D, Stimpson SA et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995; 100:126-32.
14. 14 Laochumroonvorapong P, Wang J, Liu C-C, Ye W, Moreira AL, Elkon KB, Freedman VII, Kaplan G, Perforin, a cytotoxic molecule which mediates cell necrosis, is required for the early control of mycobacterial infection in mice. Infect Immun 1997; 65:127-32.
15. 15 Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan C. Thalidomide exerts its inhibition action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
16. 16 Tsenova L, Sokol K, Freedman VH, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177:1563-72.
17. 17 Goihman-Yahr M, Requena MA, Vallecalle-Suegart E, Convit J. Autoimmune diseases and thalidomide: II. Adjuvant disease, experimental allergic encephalomyelitis, experimental allergic neuritis, of the rat. Int J Lepr 1974; 42:266-75.
18. 18 Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and two analogs on collagen induced arthritis. J Rheumatol 1998; 25:964-9.
19. 19 Schumacher H, Blake DA, Gurian JM, Gillett JR. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968; 160:189-200.
20. 20 Nau H. Species differences in pharmacokinetics and drug teratogenesis. Environ Health Perspect 1986; 70:113-29.
21. 21 Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 1981; 78:2545-8.
22. 22 Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol 1998; 55:1827-34.
23. 23 Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling DI. Thalidomide analogs and PDF4 inhibition. Bioorg Med Chem Lett 1998; 8:2669-74.
24. 24 Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120:291-300.
25. 25 Endres S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC. Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor alpha and interleukin 1β by human mononuclear cells. Immunol 1991; 72:56-60.
26. 26 Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor alpha production by human mononuclear cells. Int J Immunopharmacol 1993; 15:409-13.
27. 27 Giembycz MA, Corrigan CJ, Seybold J, Newton A, Barnes PJ. Identification of cyclic AMP phosphodiesterases 3, 4, and 7 in human CD4+ and CD8+ T-lymphocytes: role of regulating proliferation and the biosynthesis of inlerleukin-2. Brit J Pharmacol 1996; 118:1945-58.
28. 28 Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN, Feldmann M. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997; 159:6253-9.
29. 29 Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsych 1984; 17:188-90.
30. 30 Haynes DR, Gadd SJ, Whitehouse MW, Mayrhofer G, Vernon-Roberts B. Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Inflamm Res 1996; 45:159-65.
31. 31 Bromberg JS, Chavin KD, Kunkel SL. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J Immunol 1992; 148:3412-7.